Clinical Trials Logo

Clinical Trial Summary

Congenital anomalies (CA) are the most encountered cause of fetal death, infant mortality and morbidity.7.9 million infants are born with CA yearly. Early detection of CA facilitates life-saving treatments and stops the progression of disabilities. CA can be diagnosed prenatally through Morphology Scan (MS). Discrepancies between pre and postnatal diagnosis of CA reach 29%. A correct interpretation of MS allows a detailed discussion regarding the prognosis with parents. The central feature of PARADISE is the development of a specialized intelligent system that embeds a committee of Deep Learning and Statistical Learning methods, which work together in a competitive/collaborative way to increase the performance of MS examinations by signaling CA. Using preclinical testing and clinical validation, the main goal will be the direct implementation into clinical practice. This multi-disciplinary project offers a unique integration of approaches, competences, breakthroughs in key applications in human, psychological, technological, and economical interest such as the 'smarter' healthcare system, opening new fields of research. PARADISE creates an environment that contributes significantly to the healthcare system, medical and pharma industries, scientific community, economy and ultimately to each individual. Its outcome will increase impact on the management of CA by enabling the establishment of detailed plans before birth, which will decrease morbidity and mortality in infants.


Clinical Trial Description

Probe guidance: The IS guides the sonographer's probe for better acquisition of the fetal biometric plane - Basic scanning to be performed by non-expert(> 90% accuracy (AC)) Fetal biometric plane finder: The fetal planes are automatically detected, measured and stored - Insurance that all anatomical parts are checked (100% AC) Anomaly detection: unusual findings are signaled - Assistance in decision making (>90% AC) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05738954
Study type Observational
Source University of Craiova
Contact Smaranda Belciug, Assoc. Prof.
Phone 729127574
Email sbelciug@inf.ucv.ro
Status Recruiting
Phase
Start date May 4, 2022
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT05883761 - Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment
Completed NCT00766571 - Clinical and Genetic Studies of VACTERL Association
Recruiting NCT05394363 - Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
Not yet recruiting NCT05393167 - Congenital Anomalies in Infants of Diabetic Mother
Not yet recruiting NCT05547308 - Evaluation of 3D Printed Myoelectric Prosthetic Devices in Children With Upper Congenital Limb Deficiency N/A
Recruiting NCT05151042 - Digital Occlusal Wafer Versus Waferless Distal Segment Repositioning for BSSO in Skeletal Mandibular Deformities N/A
Recruiting NCT02505464 - Pregnancies Complicated by Fetal Anomalies
Recruiting NCT02595307 - Improving Informed Consent for Cleft Palate Repair N/A
Completed NCT00477594 - Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Phase 2
Completed NCT00062452 - Esophageal Motility and Airway Defenses Among Infants N/A
Recruiting NCT05763615 - 3D Modeling of the Cervico-facial Region and Cranial Nerve Tractography: IMAG 2 ORL Project N/A
Terminated NCT02351726 - Mitroflow DL Post Approval Study- North America N/A
Recruiting NCT04591392 - Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD N/A
Not yet recruiting NCT05231447 - Birth Defect Registry in South West Region of France
Completed NCT01653392 - BioThrax® (Anthrax) Vaccine in Pregnancy Registry
Completed NCT02429947 - An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients N/A
Completed NCT00607373 - Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Phase 3
Completed NCT00362180 - Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Phase 2
Active, not recruiting NCT02987387 - COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction
Completed NCT02875860 - 'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial Phase 2